Browsing Tag
Harmony Biosciences
4 posts
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
Prader-Willi syndrome: What families need to know about causes, care, and the treatment breakthrough that just changed everything
Prader-Willi syndrome explained for families and carers: causes, diagnosis, care, the 2025 FDA approval of Vykat XR, and what the latest trials mean for treatment.
ZYN002 misses pivotal Fragile X trial — What does the setback mean for Harmony’s pipeline and stock outlook?
Harmony’s ZYN002 fails key Fragile X trial, sending HRMY stock lower. Find out why placebo effects mattered and what’s next for its pipeline.
Harmony Biosciences faces FDA setback for pitolisant in idiopathic hypersomnia
Harmony Biosciences Holdings, Inc. has encountered a regulatory hurdle in its efforts to expand the use of pitolisant…